24-05-2012: Bionomics Limited has launched a Phase I/II clinical trial of its vascular disrupting agent BNC105 in women with ovarian cancer. It is anticipated that up to 134 women will be enrolled at 18 sites across Australia, New Zealand and the United States, including sites in Indiana and Wisconsin.
The trial will evaluate BNC105 in combination with current standard therapies carboplatin and gemcitabine. The study will be conducted by the Australian and New Zealand Gynaecological Oncology Group (ANZGOG) working with the National Health and Medical Research Council Clinical Trials Centre (NH&MRC CTC) in Australia and the Hoosier Oncology Group in the United States.
Bionomics CEO and Managing Director Dr Deborah Rathjen said, “The design of this clinical trial is based on robust preclinical data demonstrating synergy between BNC105 and platinum-based therapies in improving survival rates of animals with solid tumours”.